secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001193125-23-156571
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics enters consulting agreement with former CEO Mark Smith; up to $150K performance pay
--------------------------------------------------------------------------------

- Consulting agreement with former CEO Mark Smith effective May 25, 2023 for advisory services.
- Compensation includes hourly cash rate and eligibility for performance-based cash payments.
- Maximum aggregate performance payments of $150,000 tied to critical corporate objectives.
- Performance metrics determined by Compensation Committee of Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000119312523156571/0001193125-23-156571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000119312523156571/d431694d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-156571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer